ACVR2B and colorectal carcinoma: More importantly, our data have demonstrated that targeting ACVR2B may be a promising therapeutic to counteract the multi‐organ perturbations accompanying advanced metastatic CRC, as use of ACVRB/Fc proved beneficial for the sustainment of skeletal muscle mass and strength, fat mass, bone mass, and cardiac function in mice bearing CRC LM.